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Background Observational data have described the association of blood pressure (BP) with mortality as ‘J-shaped’, meaning that
mortality rates increase below a certain BP threshold.We aimed to analyse the associations between BP and prognosis
in a population of acute myocardial infarction (MI) patients with heart failure (HF) and/or systolic dysfunction.
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Methods
and results
The datasets included in this pooling initiative are derived from four trials: CAPRICORN, EPHESUS, OPTIMAAL, and
VALIANT. A total of 28 771 patients were included in this analysis. Arithmetic means of all office BP values measured
throughout follow-up were used. The primary outcome was cardiovascular death. The mean age was 65± 11.5 years
and 30% were female. Patients in the lower systolic BP (SBP) quintiles had higher rates of cardiovascular death
(reference: SBP 121–128mmHg) [adjusted hazard ratio (HR) 2.49, 95% confidence interval (CI) 2.26–2.74 for
SBP ≤112mmHg, and HR 1.29, 95% CI 1.16–1.43 for SBP 113–120mmHg]. The findings for HF hospitalization
and MI were similar. However, stroke rates were higher in patients within the highest SBP quintile (reference: SBP
121–128mmHg) (HR 1.38, 95% CI 1.11–1.72). Patients who died had a much shorter follow-up (0.7 vs. 2.1 years),
less BPmeasurements (4.6 vs. 9.8) and lower mean BP (–8mmHg in the last SBPmeasurement compared with patients
who remained alive during the follow-up), suggesting that the associations of low BP and increased cardiovascular
death represent a reverse causality phenomenon.
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Conclusion Systolic BP values<125mmHgwere associated with increased cardiovascular death, but these findings likely represent
a reverse causality phenomenon.
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Introduction
Although it is indisputable that lowering blood pressure (BP)
improves outcome of hypertensive patients,1 the threshold to
which BP should be lowered is a matter of debate and likely
to be population-specific.2–4 In addition, several observational
studies and post-hoc analyses have suggested that lowering BP
below a certain threshold may be deleterious, as reflected by
the so-called ‘J-curve phenomenon’.5–7 An observational study
in 22 672 ‘real-life’ patients with stable coronary artery disease
treated for hypertension, low systolic BP (SBP <120mmHg) and
diastolic BP (DBP <70mmHg) were associated with an increased
risk of cardiovascular events, supporting the J-curve phenomenon,
and suggesting that in patients with coronary artery disease a low
BP may be deleterious.8
Recently, the Systolic Blood Pressure Intervention Trial
(SPRINT) showed that assigning high cardiovascular risk patients
(but without diabetes or prior stroke) to an intensive BP treat-
ment arm with the goal of lowering SBP below 120mmHg vs.
a standard treatment arm with the goal of lowering SBP below
140mmHg, improved outcomes in this population, notably by
reducing the rates of heart failure (HF) hospitalizations and death
(both cardiovascular and all-cause).9 The SPRINT trial results
were also reinforced by a recent meta-analysis of trials allocating
patients in intensive vs. standard treatment arms,10 although in
this meta-analysis the mean BP in the intensive therapy group was
133/76mmHg, compared to 140/81mmHg in the standard therapy
group. Therefore, a discrepancy exists between data derived from
randomized trials and data derived from observational studies.
One potential explanation is that observational data are prone
to bias, notably residual confounding and reverse causality. The
latter is particularly relevant, i.e. it is not lower BP that causes the
adverse outcomes, but rather the ‘sicker’ patients have lower BP
near their life-end.11
The aim of the present study is to evaluate the association
between BP levels and cardiovascular outcomes in a large cohort of
acute myocardial infarction (MI) patients with systolic dysfunction
and/or HF.
Methods
Study population
The High-Risk MI Initiative consists of a previously published cohort
of pooled patient data derived from four clinical trials.12 Briefly, the
main objectives of the project are to provide a comprehensive and
statistically robust analysis of long-term clinical outcomes in high-risk
survivors of MI. The datasets included in this pooling initiative were:
the effect of Carvedilol on Outcome after Myocardial Infarction in
Patients with Left Ventricular Dysfunction trial (CAPRICORN),13,14
the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy
and Survival Study (EPHESUS),15,16 the Optimal Trial in Myocardial
Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL),17,18
and the Valsartan in Acute Myocardial Infarction trial (VALIANT).19,20
Full details of total enrolled patients, the inclusion and exclusion criteria
for each trial, the endpoints as well as the results have previously
been published.12 Each trial enrolled patients with left ventricular ..
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.. systolic dysfunction, HF or both between 12 h and 21 days after
acute MI.
The respective chairpersons of the Steering Committees of the four
trials initiated the pooling project.
The studies were all conducted in accordance with the Declaration
of Helsinki and approved by site ethics committees. All participants
gave written informed consent to participate in the studies.
Blood pressure measurements
In each trial, the investigators measured patients’ office BP after a rest
of 5min in the sitting position at each ∼4-month interval using an
automated electronic sphygmomanometer. Three BP measurements
were performed at each visit and the mean BP at each visit was used
in the present study. The main analysis was done with the arithmetic
means of all BP values measured throughout the follow-up, from the
baseline visit to the visit before an event or (in patients without
an event) up to the last visit. All analyses were done for SBP and
DBP, separately (Pearson correlation SBP/DBP =0.67). Patients were
categorized into five groups (i.e. balanced quintiles) for both SBP
and DBP.
Outcomes
The primary outcome was cardiovascular death. Secondary outcomes
were hospitalization for HF, MI, stroke, and all-cause death. We
only analysed patients with at least one BP measurement before the
outcome. Endpoints were independently adjudicated in the respective
trials.
Statistical analysis
In descriptive analyses, continuous variables are expressed
as mean± standard deviation as they were normally dis-
tributed. Categorical variables are expressed as frequencies and
proportions (%).
One-way analysis of variance (ANOVA) was used to compare BP
across quintiles. Baseline laboratory measurements were obtained
at the time of inclusion. The estimated glomerular filtration rate
(eGFR) was calculated using the Chronic Kidney Disease Epidemiology
Collaboration equation.21
Cox proportional hazard regression models were used to model
the associations between BP and long-term events both in univariable
and multivariable analysis. Cox model assumptions were verified
and BP measurements were analysed as quintiles and also con-
verted to restricted cubic splines as association with outcomes was
non-linear. In the multivariable models, the covariates were chosen
from demographic (age and gender), clinical (body mass index, smok-
ing, hypertension, diabetes, HF history, previous stroke, previous MI,
peripheral artery disease, atrial fibrillation, and heart rate), laboratory
(eGFR), and concomitant treatments (angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers, beta-blockers, and diuretics).
All variables were previously found to be clinically relevant and asso-
ciated with outcomes.22 An interaction term between BP measures
and age was pre-specified in the statistical analysis plan and was
non-significant for all outcomes (P> 0.1). No multiple imputation was
performed and only variables with <10% of missing values were used
for adjustment. Left ventricular ejection fraction, glucose, electrolytes
and haemoglobin were not included for adjustment in the models due
to a high percentage (>75%) of missing values.
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Model calibration was assessed visually by plotting the mean of
model-predicted survival at 2 years in each decile of predicted survival
against the observed survival estimated by the Kaplan–Meier method
as previously described.23
Statistical analyses were performed using the R software (The R
Foundation for Statistical Computing, Vienna, Austria). A P-value of
<0.05 was considered statistically significant.
Results
Baseline characteristics
A total of 28 771 patients were included in the present analysis (no
patients were excluded). The mean age was 65± 11.5 years and
30% were female. The overall mean follow-up was 2.0± 1.0 years
(2.1± 0.8 years in the group of patients who remained alive during
follow-up vs. 0.7± 0.6 years in those who died from cardiovascular
causes).
By quintiles of SBP, patients in the lower quintiles were younger,
more often male, active smokers, with history of previous MI, and
had lower body mass index, lower left ventricular ejection fraction,
lower serum sodium levels, higher heart rate, and better eGFR
(all P< 0.0001) (Table 1). Patients in the lower quintiles of DBP
were older, more often diabetic, and with worse renal function,
but they also had lower ejection fraction, body mass index, and
serum sodium, were more often smokers, and had previous MI
more often reported, as described for SBP (supplementary material
online, Table S1).
Mean blood pressure outcome
associations
Patients in the lower quintiles of SBP had higher rates of cardio-
vascular death compared to patients with SBP 121–128mmHg
(reference category) [adjusted hazard ratio (HR) 2.49, 95% con-
fidence interval (CI) 2.26–2.74 for SBP ≤112mmHg and HR 1.29,
95% CI 1.16–1.43 for SBP 113–120mmHg] (Table 2). Patients in
the higher SBP quintile had the lower rate of cardiovascular death
(adjusted HR 0.76, 95% CI 0.68–0.85 for SBP >137mmHg) com-
pared with the same reference group. Consistent findings were also
observed for HF hospitalization and MI (Table 2). Regarding stroke,
patients in the higher and lower mean SBP quintile had a higher
stroke risk (HR 1.38, 95% CI 1.11–1.72 and HR 1.66, 95% CI
1.32–2.10, respectively, compared with the reference group of SBP
121–128mmHg) (Table 2). Patients in the lowest quintiles of DBP
also presented an increased risk of cardiovascular death (adjusted
HR 1.88, 95% CI 1.70–2.07 for DBP ≤68mmHg and HR 1.23, 95%
CI 1.10–1.36 for DBP 69–72mmHg). High DBP was also indepen-
dently associated with an increased stroke rate (HR 1.41, 95% CI
1.13–1.75) (supplementary material online, Table S2). Sensitivity
analysis excluding patients with diabetes, stroke history and eGFR
<45mL/min/1.73m2 and additional adjustment for each trial and
oral anticoagulant use, provided similar results to those observed
in the whole population (supplementary material online, Tables S3
and S4). Restricted cubic spline graphical representations of the
relationship between BP and the outcomes of interest are depicted
in Figure 1. ..
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.. Blood pressure analysis and comparison
of patients with and without events
Compared to those who were alive, patients who died from
cardiovascular causes during the follow-up had similar absolute
BP values at baseline (i.e. at randomization) [121/72mmHg (alive)
vs. 122/72mmHg (dead)], but lower BP before the fatal event
[129/76mmHg (alive) vs. 121/72 (dead); absolute difference in SBP
+1mmHg in those who died at baseline vs. –8mmHg in those
who died in the last available recording]. Patients who died from
cardiovascular causes also had fewer BP measurements during the
follow-up (5 vs. 10 measures) and a much shorter mean follow-up
(0.7 vs. 2.1 years). Consistently, in the patients who died during
follow-up, the mean BP was lower than in patients who remained
alive (Table 3). Patients with non-fatal events (HF hospitalization,
MI, stroke) also had fewer BP measurements (∼4 vs. 9) and a much
shorter follow-up (0.7 vs. 1.9 years) compared to patients with
fatal events. Patients with HF hospitalization and MI also presented
lower last BP values compared to patients who did not have these
events (128/76 vs. 123/73 for HF hospitalization and 128/76 vs.
125/73 for MI). On the other hand, patients who had a stroke had
higher last BP values compared to patients without stroke events
(127/75 vs. 129/76) (supplementary material online, Table S5). The
associations between baseline BP values (i.e. at randomization) and
last BP values (i.e. before cardiovascular death or last available if
alive) are represented graphically in the supplementary material
online, Figures S1–S5.
Discussion
The results of the present study in a specific population of patients
with systolic dysfunction or overt HF after MI, show that BP
levels <125/75mmHg are associated with worse outcomes. The
so-called ‘J-shaped phenomenon’ (i.e. higher cardiovascular risk
below a certain BP threshold) was also observed in this large
dataset. However, we found that patients with a fatal event had
fewer BP measurements and lower last BP values compared to
patients who remained alive during follow-up. Therefore, their
mean BP approached the end-life values, suggesting a reverse
causation as explanation for these findings.
In our study, patients with lower mean BP were also those
with higher heart rate, lower body mass index, with higher pro-
portion of previous MI, and current smoking. All these variables
have been associated with worse outcomes in patients with
HF and/or MI24–27 and are likely to carry residual confounding,
accounting, in part, for the reported associations. In the present
study, after adjusting for potential confounders, having a low
SBP (<125mmHg) and DBP (<75mmHg) was associated with
non-fatal cardiovascular events (MI, stroke, HF hospitalization)
and also death (both cardiovascular and all-cause). Overlapping
results were observed in a subpopulation with less co-morbidities
(i.e. no diabetes, no previous history of stroke and with eGFR
>45mL/min/1.73m2). Interestingly, in this population having
high SBP (>140mmHg) was only independently associated with
a higher risk of stroke (but not cardiovascular death, MI or
HF hospitalization). Patients who had a stroke were the only
© 2018 The Authors
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Table 1 Demographic and baseline characteristics of the patients, for the total population and for systolic blood
pressure quintiles
Population characteristics n Total SBP Q1 SBP Q2 SBP Q3 SBP Q4 SBP Q5 P-value
≤112
mmHg
113–120
mmHg
121–128
mmHg
129–137
mmHg
>137
mmHg
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 28 771 65.0±11.5 61.2±12.3 63.0±11.9 64.7±11.2 66.6±10.4 68.6± 9.7 <0.0001
Female gender 28 771 8582 (29.8%) 1249 (22.6%) 1315 (23.1%) 1451 (27.0%) 1775 (32.0%) 2388 (43.3%) <0.0001
Heart rate (b.p.m.) 28 691 75.7±12.8 77.3±13.2 75.9±12.7 75.3±12.5 74.9±12.2 74.3±12.5 <0.0001
Mean SBP (mmHg) 27 644 124.9±14.9 105.4± 5.3 116.4± 2.3 123.9± 2.2 132.1± 2.7 146.9± 8.6 <0.0001
Mean DBP (mmHg) 27 644 74.3± 8.0 66.5± 5.7 71.6± 5.5 74.5± 5.7 77.3± 6.2 81.7± 7.4 <0.0001
Number of BP measures 28 771 8.4± 3.7 7.8± 3.7 8.7± 3.4 9.1± 3.2 9.1± 3.1 9.2± 3.2 <0.0001
BMI (kg/m2) 28 098 27.5± 4.8 26.8± 5.1 27.2± 4.6 27.6± 4.7 27.8± 4.7 28.1± 4.9 <0.0001
LVEF (%) 19 903 34.3± 8.9 32.3± 8.8 34.0± 8.6 34.8± 8.6 35.2± 8.3 36.1± 9.3 <0.0001
eGFR (mL/min/1.73m2) 27 703 70.2± 36.8 74.6± 51.9 72.6± 29.9 71.3± 29.4 68.5± 32.3 65.6± 37.2 <0.0001
Haemoglobin (g/L) 12 862 133.5±16.0 132.0± 16.5 134.3±16.0 134.2±15.8 134.1±15.9 133.0±15.7 <0.0001
Sodium (mmol/L) 13 177 139.4± 3.8 138.5± 3.8 139.1± 3.6 139.4± 3.6 139.7± 4.2 140.0± 3.5 <0.0001
Potassium (mmol/L) 13 115 4.2± 0.5 4.2± 0.5 4.3± 0.5 4.3± 0.5 4.3± 0.4 4.2± 0.5 0.001
Glucose (mmol/L) 13 088 7.4± 3.4 7.4± 3.7 7.3± 3.3 7.4± 3.6 7.4± 3.2 7.6± 3.3 0.015
Current smoker 28 735 9051 (31.5%) 1768 (32.0%) 1817 (32.0%) 1686 (31.4%) 1730 (31.3%) 1654 (30.1%) <0.0001
Previous MI 28 769 7490 (26.0%) 1481 (26.8%) 1492 (26.2%) 1324 (24.6%) 1406 (25.4%) 1372 (24.9%) 0.049
Atrial fibrillation 28 771 3754 (13.0%) 672 (12.1%) 683 (12.0%) 620 (11.5%) 742 (13.4%) 784 (14.2%) <0.0001
HF history 28 771 11 181 (38.9%) 2138 (38.7%) 2089 (36.7%) 1893 (35.2%) 2014 (36.4%) 2233 (40.5%) <0.0001
Peripheral artery disease 28 769 2357 (8.2%) 363 (6.6%) 428 (7.5%) 407 (7.6%) 506 (9.1%) 526 (9.5%) <0.0001
Hypertension history 28 771 15 570 (54.1%) 1813 (32.8%) 2369 (41.7%) 2859 (53.2%) 3583 (64.7%) 4225 (76.7%) <0.0001
Diabetes history 28 771 7386 (25.7%) 1131 (20.4%) 1225 (21.5%) 1381 (25.7%) 1561 (28.2%) 1726 (31.3%) <0.0001
Previous stroke 28 771 2264 (7.9%) 353 (6.4%) 389 (6.8%) 373 (6.9%) 470 (8.5%) 542 (9.8%) <0.0001
ACEIs 23 287 12935 (55.5%) 2698 (56.4%) 2598 (55.8%) 2382 (55.7%) 2461 (57.0%) 2366 (57.2%) 0.54
ARBs 23 287 346 (1.5%) 62 (1.3%) 55 (1.2%) 72 (1.7%) 62 (1.4%) 77 (1.9%) 0.053
Beta-blockers 26 802 17 824 (66.5%) 3497 (68.9%) 3560 (67.5%) 3392 (67.7%) 3392 (65.9%) 3330 (64.4%) <0.0001
Diuretics 28 761 13 013 (45.2%) 2515 (45.5%) 2422 (42.6%) 2251 (41.9%) 2473 (44.7%) 2587 (47.0%) <0.0001
CVM 28 742 4380 (15.2%) 1328 (23.1%) 927 (15.2%) 675 (12.4%) 717 (12.6%) 733 (12.8%) <0.0001
HF hospitalization 28 742 3385 (11.8%) 845 (15.3%) 666 (11.7%) 544 (10.1%) 589 (10.6%) 630 (11.4%) <0.0001
MI 28 742 3112 (10.8%) 781 (13.6%) 657 (10.8%) 491 (9.0%) 542 (9.5%) 641 (11.2%) <0.0001
Stroke 28 742 931 (3.2%) 181 (3.1%) 172 (2.8%) 142 (2.6%) 182 (3.2%) 254 (4.4%) <0.0001
All-cause death 28 742 5103 (17.8%) 1500 (26.1%) 1095 (17.9%) 789 (14.5%) 836 (14.7%) 883 (15.4%) <0.0001
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CVM, cardiovascular mortality; DBP, diastolic
blood pressure; eGFR, estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration formula; HF, heart failure; LVEF, left ventricular ejection
fraction; MI, myocardial infarction; SBP, systolic blood pressure.
population with a non-fatal event that had higher BP values
before the event. These findings (positive association of low
BP with all cardiovascular events and high BP only with stroke)
may support the theoretical notion that patients with coronary
artery disease may require higher BP levels to maintain coronary
perfusion.8 However, in SPRINT,9 the intensive treatment benefit
was observed regardless of the presence of previous cardiovas-
cular disease (P for interaction =0.39) and the attained mean BP
levels in the intensive treatment group were 121.4/68.7mmHg vs.
136.2/76.3mmHg in the standard treatment group. The Action to
Control Cardiovascular Risk in Diabetes (ACCORD) trial enrolled
diabetic patients at high cardiovascular risk and also targeted
SBP of <120mmHg.2 However, in the ACCORD trial intensive
treatment did not reduce the primary composite outcome of
nonfatal MI, nonfatal stroke, or death from cardiovascular causes,
but it reduced the pre-specified secondary outcome of annual ..
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. rates of stroke (although the ACCORD trial might have been
underpowered to detect between-group differences for the pri-
mary outcome as it had half of the sample size of SPRINT and
did not incorporate HF hospitalizations in the primary outcome).
In the Heart Outcomes Prevention Evaluation (HOPE)-3 trial,
BP lowering in intermediate risk persons without cardiovascular
disease also did not reduce the co-primary composite outcome of
cardiovascular death, MI or stroke, but the pre-specified subgroup
of patients with baseline SBP >143.5mmHg seemed to benefit
from anti-hypertensive therapy.28 Although patients included in the
HOPE-3 trial represent a completely different setting from those
studied herein, no event rate increase was observed in patients
with lower baseline BP. On the other hand, in observational studies
the association with adverse prognosis steeply increases with BP
levels <125/75mmHg (like in the present study),4,5,8,29 however (in
addition to potential residual confounding bias, as above referred)
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Table 2 Crude and adjusted hazard ratios for quintiles of systolic blood pressure
SBP quintiles Crude HR (95% CI) P-value Adjusted HRa (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cardiovascular death
≤112mmHg 2.128 (1.942–2.332) <0.0001 2.486 (2.257–2.739) <0.0001
113–120mmHg 1.203 (1.089–1.329) <0.0001 1.291 (1.164–1.432) <0.0001
121–128mmHg 1 – 1 –
129–137mmHg 0.998 (0.899–1.107) 0.96 0.893 (0.801–0.996) 0.041
>137mmHg 0.958 (0.863–1.064) 0.42 0.760 (0.681–0.847) <0.0001
Heart failure hospitalization
≤112mmHg 2.117 (1.884–2.378) <0.0001 2.663 (2.355–3.011) <0.0001
113–120mmHg 1.321 (1.167–1.495) <0.0001 1.497 (1.317–1.703) <0.0001
121–128mmHg 1 – 1 –
129–137mmHg 1.037 (0.910–1.181) 0.59 0.935 (0.817–1.070) 0.33
>137mmHg 1.238 (1.093–1.403) 0.001 0.934 (0.819–1.065) 0.31
Myocardial infarction
≤112mmHg 1.706 (1.525–1.91) <0.0001 1.953 (1.735–2.198) <0.0001
113–120mmHg 1.225 (1.09–1.376) 0.001 1.284 (1.137–1.45) <0.0001
121–128mmHg 1 – 1 –
129–137mmHg 1.040 (0.92–1.174) 0.53 0.958 (0.845–1.087) 0.51
>137mmHg 1.208 (1.075–1.359) 0.002 1.034 (0.915–1.169) 0.59
Stroke
≤112mmHg 1.424 (1.142–1.776) 0.002 1.661 (1.317–2.095) <0.0001
113–120mmHg 1.135 (0.907–1.419) 0.27 1.234 (0.979–1.556) 0.074
121–128mmHg 1 – 1 –
129–137mmHg 1.271 (1.02–1.582) 0.032 1.165 (0.928–1.461) 0.18
>137mmHg 1.684 (1.371–2.07) <0.0001 1.381 (1.113–1.715) 0.003
All-cause death
≤112mmHg 2.054 (1.887–2.237) <0.0001 2.410 (2.203–2.637) <0.0001
113–120mmHg 1.216 (1.109–1.332) <0.0001 1.314 (1.195–1.446) <0.0001
121–128mmHg 1 – 1 –
129–137mmHg 0.982 (0.892–1.082) 0.72 0.888 (0.803–0.982) 0.021
>137mmHg 0.989 (0.899–1.089) 0.83 0.792 (0.717–0.876) <0.0001
CI, confidence interval; HR, hazard ratio; SBP, systolic blood pressure.
P for interaction with age for SBP =0.53.
aModels adjusted for age, gender, body mass index, estimated glomerular filtration rate, smoking status, history of hypertension, diabetes, heart failure history, previous
myocardial infarction, previous stroke, peripheral artery disease, atrial fibrillation, heart rate, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers,
beta-blockers, and diuretics (not adjusted for haemoglobin, glucose, electrolytes, or left ventricular ejection fraction due to high percentage of missing values).
one should account for reverse causation bias. In a post-hoc
analysis derived from the Ongoing Telmisartan Alone and in Com-
bination With Ramipril Global Endpoint Trial (ONTARGET) and
the Telmisartan Randomized Assessment Study in ACE Intolerant
Subjects with Cardiovascular Disease (TRANSCEND)29—that
tested the efficacy and safety of angiotensin receptor blockers
on high cardiovascular risk populations—the authors found a
‘J-shaped association’ of SBP and DBP with cardiovascular death,
MI, and HF (but not stroke). Nonetheless, the authors also state
that they cannot rule out a reverse causality effect on their
findings, as multiple co-morbidities may cause BP decrease and
are associated with higher morbidity and mortality rates during
the trial. The present analysis demonstrates that patients who
died had lower BP values compared to those who remained alive
during follow-up (despite similar mean BP values at baseline). A
recent population-based study also showed lower mean BP values
in patients who died, suggesting that non-randomized epidemio-
logical associations of low SBP with higher mortality may be due to ..
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. reverse causation, because participants with lower BP values are
closer, on average, to the end of life.30 These findings suggest that
a reverse causation bias is likely to drive the present associations
as patients approaching death have lower BP values, which may
be due to poor health conditions (e.g. ‘pump’ failure, systemic
inflammation, renal disease) and deteriorating nutritional status
toward the end of life.31,32 Therefore, one should be very cautious
in mixing apples and oranges, as data from randomized controlled
trials provide much stronger evidence than observational or
retrospective analysis. Hence, the findings reported herein (and
in other observational data) may simply represent associations
between ‘sicker’ populations and increased adverse outcomes, and
any causality inference should be strongly discouraged.
Previous observational studies have yielded conflicting results for
the risk of stroke, in which the J-shaped phenomenon has not been
consistently observed.8,29,33,34 However, stroke was a less frequent
outcome in most analyses which, as a result, meant that many
lacked statistical power to assess the relationship between BP and
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Figure 1 Adjusted associations between mean blood pressure and the studied outcomes. All models are adjusted for age, gender, body
mass index, estimated glomerular filtration rate, smoking status, history of hypertension, diabetes, heart failure history, previous myocardial
infarction, previous stroke, peripheral artery disease, atrial fibrillation, and heart rate. CI, confidence interval; DBP, diastolic blood pressure;
HR, hazard ratio; SBP, systolic blood pressure.
stroke. Moreover, in SPRINT, stroke rates were not reduced by
intensive BP lowering,9 but it should be acknowledged that stroke
was a component of the primary outcome (and not the primary
outcome on which sample size calculations were based), hence
this trial was also underpowered to assess the effect of intensive
BP lowering on stroke. Our study population had more than 900 ..
..
..
..
..
..
..
..
.. adjudicated stroke events (almost twice the total primary outcome
events reported in SPRINT) and allows the study of the association
between BP levels and stroke risk in an adequately powered fashion,
and show that both higher and lower BP are associated with
higher stroke rates, suggesting a J-shaped phenomenon in this
population.
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Table 3 Patient characteristics and blood pressure
analysis according to the primary outcome event
Alive
(n= 24 371)
CV death
(n= 4400)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 64.0± 11.3 70.3±10.7 <0.0001
Female 6966 (28.6%) 1616 (36.7%) <0.0001
Heart rate (b.p.m.) 75.2± 12.5 78.9±13.8 <0.0001
Current smoker 8691 (35.7%) 1809 (41.2%) <0.0001
Body mass index (kg/m2) 27.6± 4.8 27.1± 4.9 <0.0001
eGFR (mL/min/1.73m2) 71.8± 38.0 61.4± 27.7 <0.0001
Myocardial infarction 5687 (23.3%) 1803 (41.0%) <0.0001
Atrial fibrillation 2781 (11.4%) 973 (22.1%) <0.0001
Heart failure 8809 (36.1%) 2372 (53.9%) <0.0001
Peripheral artery disease 1790 (7.3%) 567 (12.9%) <0.0001
Hypertension 12881 (52.9%) 2689 (61.1%) <0.0001
Diabetes 5861 (24.0%) 1525 (34.7%) <0.0001
Stroke 1689 (6.9%) 575 (13.1%) <0.0001
Mean SBP (mmHg) 125.3±14.6 121.4±16.0 <0.0001
Mean DBP (mmHg) 74.6± 7.7 71.8± 9.4 <0.0001
Baseline SBP (mmHg) 120.8±16.6 121.8±17.6 0.0002
Baseline DBP (mmHg) 71.7±10.7 71.6±11.5 0.45
Last SBP (mmHg) 128.5±19.7 120.5± 21.3 <0.0001
Last DBP (mmHg) 76.0± 10.9 71.7±12.5 <0.0001
Number of SBP measures 9.8± 2.8 4.6± 2.7 <0.0001
Number of DBP measures 9.8± 2.8 4.6± 2.7 <0.0001
Follow-up (years) 2.1± 0.8 0.7± 0.6 <0.0001
CV, cardiovascular; DBP, diastolic blood pressure; eGFR, estimated glomerular
filtration rate; SBP, systolic blood pressure.
The data presented herein are the first to describe the asso-
ciation of mean BP with several cardiovascular outcomes in a
large population of MI patients with systolic dysfunction and/or HF.
Importantly, these findings suggest that the association between
low BP levels and worse cardiovascular outcomes may be driven
by a reverse causation phenomenon (as also suggested from
population-based studies30), hence caution is warranted when
interpreting associations between BP and outcomes in observa-
tional data.
Limitations
Several limitations of this study should be acknowledged: (i) this
is a post-hoc analysis of ‘high-risk’ acute MI trial populations in
which hypertension history (although more than half of the patients
were hypertensive) was not an entry criteria, hence the results pre-
sented herein cannot be extrapolated to other populations; (ii) the
retrospective nature of these results makes them prone to con-
founding and causality cannot be presumed nor even suggested; (iii)
despite extensive adjustment, many unmeasured variables could
account for residual confounding bias; (iv) the lower BP values
observed near the end of life, and the lower mean BP described
in patients who died from cardiovascular causes suggest a reverse
causation phenomenon as responsible for the associations of low
BP with cardiovascular death; however, this phenomenon should
be highlighted and data from randomized controlled trials should ..
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.. be preferred to observational associations; (v) patients with car-
diovascular events also had a shorter follow-up, which may have
contributed for reverse causation to have influenced the associa-
tions described in the present study; (vi) BP measurements were
made at the office in trial visits and did not use standardized tech-
niques across trial and centres; however, given the great number
of patients and measures the occurrence of systematic error is
unlikely; (vii) clinical variables and outcome events were ascer-
tained in each trial by the study investigators and independent
adjudication committees, respectively. Errors in clinical records and
event adjudication might have occurred; however, these are also
unlikely to be systematic and influence the associations presented
herein in a systematic fashion; (viii) medication doses or changes
during follow-up are not available in the dataset, therefore we can-
not ascertain which patients had treatment intensification during
the trial; (ix) biomarkers (e.g. N-terminal pro-B-type natriuretic
peptide and troponins) could help in better stratifying patients’ risk;
however, biomarker data were not available in the dataset; (x) the
datasets were transferred by the sponsors with no information on
treatment allocation, hence the possible influence of the treatment
allocation on BP and outcomes cannot be assessed in the present
study.
Conclusions
The results of the present study in a selected population of MI
patients with systolic dysfunction or HF, show that BP values
<125/75mmHg were associated with worse cardiovascular out-
comes. Patients with a fatal event had fewer BP measurements
and lower mean BP near the deadly event. Therefore, their mean
BP was lower, suggesting that a reverse causation phenomenon
accounts for the association of low BP and cardiovascular death
in this setting.
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